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1  Purpose 
The purpose of this RFC is to introduce a standardized framework for the engineering of 
customizable non-ribosomal peptide synthetases (NRPS) and their application for in vivo and 
in vitro synthesis of short non-ribosomal peptides (NRPs) of user-defined sequence and 
structure.   
 
 
2  Relation to other BBF RFCs 
BBF RFC100 updates RFC57 describing the “Assembly of BioBricks by the Gibson method”, 
which was proposed by the iGEM team Cambridge 2010. Specifically, RFC100 adopts the 
Gibson assembly strategy proposed by RFC57 for cloning of large bacterial NRPS 
expression constructs. BBF RFC100 also updates RFC99 describing the “HiCT: High 
Throughput Protocols for CPE Cloning and Transformation”, which was proposed by the 
iGEM team Heidelberg 2013. 
 
 
3  Copyright Notice 
Copyright (C) The BioBricks Foundation (2013). All Rights Reserved. 
 
 
4  Introduction to the Synthesis of Customized Peptides by 
Non-Ribosomal Peptide Synthetases 
4.1  State of the Art in Peptide Synthesis 
Solid-phase synthesis of peptides was pioneered by Robert Bruce Merrifield in 1963 
[Merrifield, 1963] and still represents the state of the art chemical method for manufacturing 
custom small peptides. It enables the stepwise assembly of peptides from single amino 
acids, also allowing for incorporation of non-essential amino acids into peptide chains. 
Although solid state peptide synthesis is nowadays standardized and automated, the method 
has an important limitation: it is expensive when applied for industry-scale production of 
synthetic peptides.  
Recombinant peptide synthesis represents an interesting alternative to chemical peptide 
synthesis, as it is easily scalable once the production is up and running. However, this 
approach is currently restricted to peptides composed mostly of proteinogenic amino acids. 
Furthermore, developing an efficient peptide production strain or establishing a 
corresponding in vitro translation systems is laborious and thus, also costly and time 
consuming. 
As consequence of these limitations, the interest of industry to invest into the development of 
peptide-based applications including peptide drugs has been rather low in the past, calling 
for alternative peptide production methods which are cost-efficient, automatable, scalable 
and fast. 
4.2  Non-Ribosomal Peptide Synthesis 
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Non-ribosomal peptides (NRPs) are secondary metabolites produced by microorganisms, 
e.g. bacteria and fungi, where they have various functions ranging from antibiotics to 
pigments and chelators of toxic metal ions. Notably, non-ribosomal peptide synthesis does 
not require mRNA to direct the sequence of amino acid monomers incorporated into the 
growing peptide chain. Instead, NRPSs are organized in distinct functional subunits, the so-
called NRPS modules. During NRP synthesis, every NRPS module recognizes one specific 
amino acid substrate and catalyzes the formation of a peptide bond between the amino acid 
substrate and the nascent peptide chain, which is handed over from the previous NRPS 
module. In contrast to ribosomal peptide and protein synthesis, NRPSs can incorporate 
proteinogenic as well as non-proteinogenic amino acids substrates (about 500 different 
amino acid building blocks are currently known) into NRPs. Moreover, NRPs may be linear 
as well as circularized. This leads to an enormous variability of NRPs explaining their diverse 
functions in nature. 
 
Every NRPS module can again be subdivided into different functional domains. A new amino 
acid is first adenylated by the A-domain and then bound to the T-domain (thiolation domain) 
via a thioester bond. The C-domain catalyzes the condensation of an existing peptide chain - 
which is bound to the T-domain of the previous module - and the amino acid of the next 
module. The T-domain itself does not exhibit any substrate specificity but is just a carrier 
domain to keep the peptide attached to the NRPS module complex. The core of every T-
domain is a conserved 4’-phosphopanthetheinylated (4’-PPT) serine. The 4’-PPT residue is 
added by a 4’-Phosphopanthetheinyl-transferase (PPTase), which brings the NRPS apo-
enzyme to its active holo-form. 
NRPSs are known to have a modular architecture, with single modules being specific for a 
specific amino acid as described above. The single modules can be connected covalently to 
form large multi-module-proteins. However, single modules can also associate via protein-
protein interactions, mostly via so called communication domains.  
 
We and others have shown, that NRPS modules can be exchanged and even entirely 
shuffled in order to create new NRPSs synthesizing novel peptides [iGEM Team Heidelberg 
2013, 2013.igem.org/Team:Heidelberg; Mootz et al. 2000; Nguyen et al. 2006, Stachelhaus 
et al. 1998, Finking & Marahiel 2004]. These custom NRPS may include (1) modules derived 
from a single NRPS pathway, (2) modules derived from different NRPS pathways from a 
single species, (3) modules derived from NRPS pathways from different species and (4) 
entirely synthetic modules composed of domains of varying origin. It was furthermore found 
to be generally possible to exchange domains comprised in a module for another domain 
conferring the same or similar functionality, emphasizing the modular architecture of NRPSs 
on several levels.  
Thus, NRPSs represent highly versatile and flexible platform for the in vivo synthesis of 
completely synthetic peptides.  
 
 
4.3 A Standardized Framework for the engineering of  
 customized NRPSs 
Here we propose a standardized framework for the engineering of customized NRPSs 
catalyzing the synthesis of user-defined NRPs. The framework consists of (1) the 
NRPSDesigner, a software tool for the in silico design of user-defined NRPSs, (2) a platform 
for standardized cloning and expression of NRPSs in different bacterial hosts and (3) a 
quality control procedure for the validation of NRP production (Figure 1). Following this 
framework enables a user to easily engineer customized NRPSs and thereby produce 
synthetic NRPs within a minimal amount of time and in a cost-efficient and easily scalable 
manner.  
 
The user may provide any custom NRP sequence as input for the NRPS designer (Figure 
1.1), which is a completely automated software for the in silico design of synthetic NRPSs 
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(for description of the NRPSDesigner buildup see Appendix A). The software is based on a 
manually curated database of NRPS modules, each of which represents a unit responsible 
for incorporating a specific amino acid building block into the corresponding NRP chain. 
Moreover, the user can also add novel modules not present in the database or completely 
synthetic modules, thereby enhancing the range of possible amino acid substrates and 
modifications available for the corresponding NRPs. 
 
Additionally, the NRPSDesigner offers the possibility to tag the custom NRPs with the blue 
NRPS pigment indigoidine. The user may add an engineered indigoidine synthetase 
[2013.igem.org/Team:Heidelberg/Project/Indigoidine] module as last module to the 
corresponding custom NRPS in the NRPSDesigner leading to a blue coloring of the NRP. 
 
Labeling NRPs with indigoidine has several advantages, as it enables 
 
1) a direct visualization of successful cloning, NRPS expression and NRP  
production by the custom NRPS (colonies turn blue on plates) 
2) an easy qualitative analysis of the NRP produced by thin layer chromatography (TLC) 
avoiding the need for Mass Spectrometry (MassSpec) analysis 
3) a direct quantification of NRP productivity of different clones in a simple, photometric 
measurement 
4) an easy purification of indigoidine-tagged peptides (e.g. by HPCL collecting fractions 
with absorption maxima at 600 nm) 
 
 
 
After finalizing the NRPS design the user is provided with a set of Gibson primers and 
corresponding PCR template BioBricks (note: if there are no BioBricks available, the DNA of 
the NRPS module donor organism is used as template). Cloning is performed by applying a 
Gibson assembly strategy optimized for cloning of large expression cassettes (Figure 1.2) 
(note: a single NRPS module is about 1000 amino acids long). The so obtained vector can 
then directly be transformed into the host strain carrying a PPTase expression cassette of 
choice in order to start in vivo NRPS production. 
In order to validate NRPS functionality and successful NRP expression (Figure 1.3), the user 
must perform a qualitative control analysis either by MassSpec (for untagged NRPs; note: 
requires purification of the corresponding peptides) or by a photometric absorption 
measurement followed by TLC (for indigoidine-tagged NRPs). 
In the following section, we list detailed protocols that should enable the synthetic biology 
community to adopt and use the framework described in this RFC.  
 
We furthermore introduce concepts to the extension of the framework (section 6) towards 
high-throughput production of synthetic NRPs and combinatorial NRP libraries and in vitro 
synthesis of NRPs. 
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Figure 1: Schematic overview of the proposed standardized framework for the production of 
customized, synthetic non-ribosomal peptides. (1) In silico design of NRPS using the 
NRPSDesigner: the NRPSDesigner is based on a manually curated database of NRPS modules from 
which it can choose modules to predict the optimal sequence for a customized NRPS. Instructions on 
how to use the NRPSDesigner can be found in section 5.1 and 5.2. (2) Cloning and expression of 
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NRPS: the NRPSDesigner outputs a Gibson cloning strategy for the assembly of the desired NRPS. 
The transformation of the Gibson-assembled NRPS constructs in host strains carrying BioBrick 
PPTase plasmids will allow for the expression of the customized NRP. Protocols on how to clone and 
and express NRPS construct are described in section 5.3.1. (3) Quality control proofing successful 
NRP production: validation strategies for the expression of the NRP depend on the design of the NRP 
as chosen by the user. Easy validation by screening for a blue phenotype of the host strains and 
expression control by TLC is enabled if the users choose to incorporate an indigoidine-tag in step (1) 
and (2). Detailed description of how to validate the expression of the custom NRP is provided in 
section 5.3.2. 
 
 
 
5  Protocols for the Synthesis of Customized Peptides by 
 engineered Non-Ribosomal Peptide Synthetases 
The user SHOULD use the NRPSDesigner for the in silico design of user-defined NRPSs 
(section 5.1). In addition, the user MAY extend the database on which the NRPSDesigner 
relies by adding new domains of defined substrate specificity (section 5.2). For the in vivo 
production of custom NRPs and the subsequent quality control, the users SHOULD follow 
the instructions given in section 5.3. 
 
 
5.1 The NRPSDesigner: a comprehensive software guide to optimize 
non-ribosomal peptide synthesis 
For the prediction of customized NRPSs by the NRPSDesigner the user MUST follow the 
procedure described below: 
 
1. The user MUST enter the amino acids that constitute the desired peptide. 
 
2. The user MUST choose between L- and D- conformation and MAY include possible 
modifications (e.g. oxidation or methylation). 
 
3. The user also MAY choose to add an indigoidine tag, which eases detection and 
quantification of the expression of the desired peptide. 
 
4. Upon peptide entries by the user, the NRPSDesigner determines required modules and 
domains and computes the best-fitting combination. The software output to the user 
includes a suggestion for an assembly strategy that is based on Gibson cloning. 
 
5. The user SHOULD consider suggested primer sequences though he MAY adapt the 
primer-binding regions, which can be easily customized with the NRPSDesigner. 
 
6. The user SHOULD use Gibson cloning for the assembly of the fragments as described in 
the BBF RFC 57. 
 
 
5.2 Extending the database: Sharing your expertise in NRPS with the 
synthetic biology community. 
Besides the design of novel, synthetic non-ribosomal peptides, the user MAY also extend the 
underlying database of the NRPSDesigner in order to share knowledge about NRPS 
domains and modules. Herefore,  
 
1. the user MUST register with a username and a valid email address; 
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2. the user MUST enter i) the DNA sequence in FASTA format or as plain text, ii) the 
respective source (i.e. a native organism or a BioBrick plasmid) and iii) the gene name; 
 
3. the user SHOULD add a description for his entry; 
 
4. the user SHOULD annotate the synthetic pathway if the sequence it originated from is 
annotated. Upon fulfillment of all required entries, the NRPSDesigner predicts domains 
and their specificity of the putative NRPS using Hidden-Markov-Models (HMMs). 
Subsequently, 
 
5. the user MAY define personal recommendations for domain boundaries, e.g. based on 
multiple sequence alignments that are also offered by the NRPSDesigner; 
 
6. the user MAY add a custom description of each domain; 
 
7. the user MUST submit the final data form. 
 
 
5.3 Working with NRPS: Creating custom NRPSs for in vivo NRP 
synthesis. 
5.3.1. Cloning and Expression of NRPS 
 
1. Expression of NRPS construct MUST be conducted in host strains expressing the 
following PPTase expression constructs or corresponding derivates thereof: sfp 
(BBa_K1152009), svp (BBa_K11520010), entD (BBa_K1152011), delC (BBa_K1152012. 
Therefore, four different chemo-competent or electro-competent host strains derived from 
the same species carrying each a single PPTase construct MUST be created. Host cells 
SHOULD either be E. coli, Bacillus or Streptomyces strains. In order to reduce time and 
material costs, the four host strains (e.g. E. coli BL21 transformed with either PPTase 
construct) SHOULD be made competent and equal volumes of each competent PPTase 
expression strain SHOULD be mixed and aliquoted afterwards. Thereby transformation 
into the four host strains MAY be performed in a single vial. 
 
2. For amplification of the fragments, the user SHOULD use the primers proposed by the 
NRPSDesigner and MUST use a backbone with an antibiotic resistance marker other 
than that present on the PPTase-encoding plasmid. 
 
3. The assembly of the NRPS plasmid MUST be done by Gibson [BBF RFC 57] or CPE 
cloning [BBF RFC 99], depending on the size and number of fragments to assemble. 
CPE Cloning MAY be used for up to four fragments, Gibson Cloning MUST be used for 
more than four fragments and NRPS expression constructs above 10 kbp in size. After 
cloning, product MAY be purified by isopropanol precipitation. 
 
4. Transformations of the custom host strain with the synthesized NRPS MAY be conducted 
with the cloning mixture or the purified assembly product. 
 
5. NRPS-transformed custom host strains MUST be selected for the presence of both 
constructs by two-fold antibiotic selection. 
 
6. Selection for positive colonies: 
 
a) If NRPS was fused with blue pigment module: the user MUST pick a single blue 
colony 
 
RFC 100                                                       Synthesis of Customized Non-Ribosomal Peptides  
- 7 - 
 
b) If NRPS was not fused to blue pigment module: the user MUST pick 5-10 colonies 
and MUST validate the success of the assembly by test restriction digests and   
sequencing 
 
 
5.3.2. Quality Control proofing successful NRP production 
 
1. The user MUST confirm peptide production 
 
a) If NRPS was fused with blue pigment module: the user MUST conduct thin-layer 
chromatography (for details see Appendix B2) with NRPS-blue pigment fusion 
peptide and blue pigment control; the user MAY photometrically quantify NRP 
production by measuring the amount of blue pigment; the user MAY also conduct 
Mass Spectromety (for details see Appendix B3) to confirm peptide production 
 
b) If NRPS was not fused to blue pigment module: the user MUST enrich and purify the 
peptide (for purification protocols see Appendix B.1). The user MUST conduct Mass 
Spectrometry to confirm peptide production 
 
6. Extension of the Framework 
This RFC mainly focuses on the in vivo synthesis of single, customized NRPs. However, we 
believe that this framework is readily expandable towards a high-throughput engineering of 
combinatorial NRPs libraries both produced in vivo or in vitro. Such libraries would be of high 
value and could in future become a valuable resource for the development of novel NRP-
based antibiotics including ionophores [Duax et al., 1996] or metal ion chelating agents.  
 
 
6.1. High-throughput production of synthetic NRPs and combinatorial  
NRP libraries 
Taking advantage of the possibility to label custom NRPs with an Indigoidine-Tag, the 
construction of NRP libraries MAY be automated to a large extend. To this end, we propose 
the following guidelines in order to expand and parallelize the framework described above: 
 
1.  The NRPSDesigners’ input interface SHOULD be extended in order to enable the input of 
multiple NRP sequences from ordered tables uploaded by the user. Users MUST use 
Indigoidine as the last amino acid unit for each input NRP. 
 
2. Cloning of NRPSs expression constructs MUST be parallelized and standardized, e.g. by 
performing parallelized Gibson Assembly (refer to BBF RFC 57 and BBF RFC 62) or 
HiCT cloning (refer to BBF RFC 99) in multi-well formats and small reaction volumes. 
Standard NRPS expression backbones, such as the pSB1C3 or pSB3C5 backbone, 
containing standard promoters and terminators SHOULD be employed. 
 
3. Gibson or HiCT assembly mixes SHOULD be transformed into four different chemo-
competent or electro-competent host strains derived from the same species. Host cells 
SHOULD either be E. coli, Bacillus or Streptomyces strains transformed with any of the 
following four PPTase expression constructs or corresponding derivatives thereof: sfp 
(BBa_K1152009), svp (BBa_K11520010), entD (BBa_K1152011), delC 
(BBa_K1152012). In order to reduce time and material costs, the four host strains (e.g. E. 
coli BL21 transformed with either PPTase construct) SHOULD be made competent and 
equal volumes of each competent PPTase expression strain SHOULD be mixed and 
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aliquoted afterwards, preferably directly into a multiwell format. Thereby transformation 
into the four host strains MAY be performed in a single vial.  
 
4. Transformation mixes MUST be spread on agar plates containing appropriate growth 
medium (this MAY be LB-Broth or 2-YT for E. coli) with corresponding antibiotics and 
incubated for 12-96 h at 21-37°C. 
 
5. Picking of blue colonies (coloring refers to successful NRP expression) and inoculation of 
liquid cultures SHOULD be performed by a cloning robot 24-72 h after transformation. 
White colonies MUST NOT be picked. The robot SHOULD pick at least three clones per 
construct and SHOULD inoculate liquid cultures preferably in small scale in a multi-well 
plate format. This format MAY be a 96-well format with 200 µl culture volume. 
 
6. Liquid cultures should be grown at 30°C for 12-48 h and coloring of the cultures in the 
different wells SHOULD be monitored by photo-absorption measurements (see Appendix 
B.4) in order to identify highly productive strains.   
 
7. 180 µl of liquid cultures should be used for NRP purification (see Appendix B.1) which 
MAY again be performed in small scale in a multi-well format or also automatized in case 
larger scales would be required. 5 µl 50% glycerol should be added to each well 
containing the remaining 20 µl of the liquid cultures and the multi-well plate should be 
stored at - 80°C. 
 
8. NRP functionality tests MAY be performed directly in multi-well format in order to identify 
the NRP candidates showing the required function.   
 
9. Thin Layer Chromatography (TLC) should be performed for all NRP samples positive in 
the functional assays. An indigoidine-only control MUST be loaded in parallel with all 
NRP samples onto the TLC. NRPs showing a slower migration compared to the 
indigoidine-only control SHOULD be considered positive. 
 
10. Positive NRP samples from point 8 MAY be analyzed further by MassSpec (see 
Appendix B.3) in order to confirm the correct peptide sequence.  
 
11. Production of NRP candidates of interest MAY subsequently be up scaled in vivo or even 
performed in vitro (see section 6.2) and purification of NRPs MAY be done by liquid 
chromatography (e.g. HPLC) collecting the fractions that MUST show highest 
absorbance at 600 nm. 
Note: The indigoidine module MAY be removed from NRPSs if labeling of the corresponding 
NRPs is no longer desired.   
 
6.2  In vitro NRPs Synthesis  
NRPSs may also be purified from their bacterial host and used for in vitro synthesis of NRPs. 
This might simplify the purification of NRPs and yield products of high purity. In addition, in 
vitro NRP synthesis can easily be optimized by varying buffer and incubation conditions. 
 
1. NRPSs SHOULD be tagged C-terminally with affinity tags enabling the purification of the 
corresponding NRPS. Suitable tags MAY be the His6-, Myc-, or Flag-Tag. 
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2. NRPSs MUST be purified applying any affinity-based purification protocol well known in 
the arts. 
 
3. NRPSs MUST be incubated under appropriate buffer conditions and in presence of all 
amino acid substrates to be incorporated into the corresponding NRP. Detailed protocols 
describing in vitro NRP synthesis can be found elsewhere [Mootz et al. 2000]. 
 
4. NRPs SHOULD be purified (see Appendix B.1) following in vitro synthesis. 
 
5. If the produced NRP is labeled with indigoidine, the NRP should be analyzed by TLC as 
described in Appendix B.2. 
If the produced NRP is not labeled with indigoidine, the NRP should be purified and 
analyzed by MassSpec as described in Appendix B.3. 
 
7.  In vitro NRP production MAY be further optimized by varying single or multiple 
parameters influencing NRP synthesis. These MAY include but are not limited to the 
buffer conditions, NRPS(s) concentration(s), amino acid substrate concentrations or 
incubation temperature and time. 
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Appendix 
Appendix A.  Buildup of the NRPSDesigner and Graphical User 
Interface 
The NRPSDesigner facilitates the prediction and synthesis of non-ribosomal synthetases 
(NRPS) which will catalyze the customized assembly of non-ribosomal peptides. The 
software itself is split into a command-line executable comprising the core algorithm and a 
web-interface providing easy access to the functionality. The NRPSDesigner contains three 
main functions: i) Data storage, ii) in silico NRPS prediction and iii) design of an NRPS 
synthesis strategy. 
 
i) The manually curated database of the NRPSDesigner stores information of about 
600 NRPS domains, their DNA coding sequences and respective substrate 
specificities (database entries mainly retrieved from  [Ansari et al., 2004]). Users 
are also able to enter new domains and pathways into the database by providing 
the coding sequence of their NRPS. Additionally, the database can also be 
extended with curated content using automated domain prediction based on 
Hidden Markov Models. 
 
ii) The NRPSDesigner uses the stored information from its database to predict the 
optimal domain sequence that is able to produce a user-defined NRP. The 
prediction algorithm is based on the phylogenetic distances of the host organisms 
from which the database entries were derived: combinations of domains from 
closely related organisms have a higher probability to form a functional NRPS 
than domain combinations involving organisms which are far apart on the 
taxonomic tree. The taxonomic distance is currently determined from lineage 
information available in the NCBI taxonomy database. 
 
 
iii) To facilitate the transition from in silico NRPS design towards expression of the 
desired NRPS, the Gibthon iGEM software tool of Cambridge 2010 for Gibson 
primer construction was embedded into the web-interface of the NRPSDesigner. 
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Based on the NRPS sequence predicted by the design software, the Gibthon tool 
calculates primers and PCR conditions for optimal Gibson assembly. To enable 
the easy detection of the NRPS expression in the host strains, the NRPSDesigner 
database contains the necessary domain sequencing for combining the nascent 
peptide with an indigoidine-tag (Project description: http://igem2013.bioquant.uni-
heidelberg.de/NRPSDesigner; GUI of the NRPSDesigner: 
http://2013.igem.org/Team:Heidelberg/Project_Software). 
 
A step-by-step tour through the graphical user interface depicting the design of an NRPS 
for the synthesis of an NRP composed of valin-indigoidine is shown in Figure 2. 
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Appendix B.  Supplementary  Protocols 
 
B1. Peptide Purification 
 
a) Purification of NRPs tagged with indigoidine for expression control by TLC  
1 ml of IPTG-induced, blue culture is spun down at full speed (14,000 rpm) for 20 
minutes, washed in 1 ml of methanol and centrifuged once more for 5 minutes at 
14,000 rpm. Methanol is discarded and samples are allowed to dried. Lastly, dried 
samples are dissolved in 200-400 µl DMSO. 
  
Note: For evaluation of expression over time this protocol is not recommended, as it is 
not suitable for quantification.  
 
b) Purification of NRPs lacking an indigoidine tag for expression control by 
MassSpec  
  
3 ml of LB-medium with appropriate antibiotic are inoculated and incubated at 37°C 
overnight. At OD600 = ~0.6, culture is spun down for 30 minutes at 3750 rpm and 
4°C, supernatant is discarded and pellet washed with M9 minimal media. Samples 
are centrifuged once more and resuspended in 50 ml M9 minimal media. Following 
an incubation time of 12 hours (OD600=~0.6) cells are induced with 1 mM IPTG. 
  
After another 12 hours, samples are spun down for 45 minutes at 3750 rpm and 4°C, 
and supernatant is separated from pellet: 
   
The Pellet is resolved in 500 µl 1x PBS and subsequently cells are lysed by ultra-
sonification (3x20 s on ice) and the sample is centrifuged. Supernatant is transferred 
to 1.5 ml tubes and frozen in liquid nitrogen. The sample is ready for mass 
spectrometry. 
  
Note: In order to remove aqueous and ionic residues, it is recommended to lyophilize 
the purified sample before subjection to MassSpec. Lyophilization is carried out for 12 
hours at ~-45°C and ~0,1 mbar. The lyophilisate is resuspended in 500 µl methanol, 
vortexed and spun down. Supernatant is transferred to a 1.5 ml tube and frozen in 
liquid nitrogen. The sample is ready for mass spectrometry. 
  
Optionally: For evaluation over time, 7.5 ml culture are taken at several time points 
(e.g. 8.5 h, 12 h, 24 h and 48 h) and purified as described above. 
 
B2. Thin Layer Chromatography 
 
TLC is carried out on silica-gel as immobile phase and dichloromethane as mobile 
phase. For the procedure, a 50 ml beaker is filled with ~15 ml dichloromethane and 
allowed to stand for about 10 minutes to let the dichloromethane-vapor fill the beaker. 
As Indigoidine is light-sensitive, the beaker has to be covered with aluminium foil in 
order to prevent direct light irradiation.  Sample purified according to Appendix B1a) 
as well as an indigoidine-only control (purified in analogy to the sample) are spotted 
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approximately 0.5 to 1 cm above the lower edge of a TLC plate coated with silica-gel. 
The TLC plate is placed in the beaker and TLC is allowed to run until the solvent front 
is at two thirds of the TLC plate. NRPs showing a slower migration compared to the 
indigoidine-only control are considered positive (compare to Figure 3) 
 
  
B3. Recommended approach for the quantification of indigoidine production using OD 
measurement. 
Detecting the amount of the NRP expressed by the bacterial host strain is desirable. By 
tagging the NRP with indigoidine, the amount of the fusion peptide can be determined by 
quantifying the amount of blue pigment present in the cells. As the amount of blue pigment is 
proportional to the amount of the NRP of interest, a method for the quantification of the blue 
pigment will yield information about the expression of the NRP. Quantification of the pure 
indigoidine pigment can be easily achieved by optical density (OD) measurements at its 
maximum wavelength of about 590 nm.  
In cellular culture, indigoidine quantification by OD measurements is impaired. Cellular 
density of liquid cultures is standardly measured as the optical density (OD) at a wave length 
of 600 nm, i. e.  the absorption peak of indigoidine interferes with the measurement of cell 
Figure 3: Validation of the expression of an indigoidine-
tagged NRP by thin layer chromatography. The purified 
Valin-Indigoidine sample and the Indigoidine-only control 
can clearly be separated by TLC (TLC plate coated with 
silica;  running buffer: dichloromethane). The slower 
migration of the NRP compared to the indigoidine-only 
control serves as expression proof of the NRP.  
RFC 100                                                       Synthesis of Customized Non-Ribosomal Peptides  
- 15 - 
 
density at the preferred wave length (compare to Figure 3, grey dashed line).   Thus, for 
measurement of NRP expression without time consuming a priori purification of the tagged-
protein, a method to separate the cellular and pigment-derived contributions to the OD is  
required (compare to Figure 3, brown and blue lines, respectively).  The method of choice, as 
described by Myers et al.[2013], requires the OD measurement of  cell culture at two distinct 
wavelengths: the robust wave length ODR and the sensitive wave length ODS.  The 
concentration of indigoidine will have to be deducted from measurements at ODS = 590 nm:  [𝐼𝑛𝑑𝑖𝑔𝑜𝑖𝑑𝑖𝑛𝑒] =  𝑂𝐷𝑆,+𝑃 − 𝑂𝐷𝑆,−𝑃 
with 𝑂𝐷𝑆,+𝑃 being the overall OD measurement and 𝑂𝐷𝑆,−𝑃 being the scattering contribution of 
the cellular components at the sensitive OD.  
The scattering contribution of the cellular compenents at ODS  (ODS,-P ) can be calculated from the 
scattering contribution measured at the robust wave length according to the following formula:  
𝑂𝐷𝑆,−𝑃 =  𝛿 ∗ 𝑂𝐷𝑅 
The correction factor δ is be determined by measuring the OD of pure cellular culture without 
indigoidine at both the wavelength  𝑂𝐷𝑆,−𝑃 and 𝑂𝐷𝑅 and calculating their ratio.  
Finally, the indigoidine production can be determined as 
Figure 4: Quantification of dye in cellular culture by 
OD measurements at robust and sensitive 
wavelengths. The contribution of the scattering by the 
cellular components at the sensitive wavelength, i.e. 
590 nm for indigoidine has to be subtracted from the 
overall OD at this wavelength. For a detailed description 
of the calculation refer to text below.   
Figure adopted from [Myers, 2013] 
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[𝐼𝑛𝑑𝑖𝑔𝑜𝑖𝑑𝑖𝑛𝑒] = 𝑂𝐷𝑆,+𝑃 − 𝛿 ∗ 𝑂𝐷𝑅 
 
For the calculation of the cellular component when measuring indigoidine producing liquid 
cell cultures, OD measurement at 800 nm as robust wavelength is recommended. By the 
approach described above, quantitative observation of the indigoidine production in a liquid 
culture over time as well as the indigoidine production in relation to the cell growth can be 
conducted.  
Background correction i. e. the contribution of the culture medium to the OD measurement is 
achieved by subtracting the mean of pure culture medium replicates from all OD values 
measured. 
Instructions and suggestions on how to prepare OD measurements of multiple cell cultures to 
quantify indigoidine production in a parallelized manner are described below.  
96-well plates are prepared with 100 μl LB-medium/well containing appropriate antibiotics) 
and each well is inoculated with single colonies (in duplicates) from plates positive for the 
transformation experiments i.e. from plates with blue colonies. Two sets of negative controls 
are also inoculated on the plate: First, pure medium serving as the baseline for background 
correction for the OD measurements. Second, transformation controls accounting for 
potential differences in cell growth due to expression of proteins contained on the plasmids, 
i.e. the antibitotic resistance gene and IndC. In this set of controls, the plasmids coding for 
the IndC-constructs carry a randomly generated sequence instead of the T-domain.  A 
second 96 well plate es prepared with 180 µl LB-medium/well for the measurement itself. 
The 96-well plate containing the pre-cultures of the co-transformed colonies is inoculated for 
24 hours at 37°C. Subsequently, 20 µl of the pre-culture are transferred to the measurement 
plate. The absorbance of the bacterial cultures is measured at critical wavelengths of 590 
and 800 nm. For time-resolved measurement of indigoidine, hence NRP expression, the OD 
of each well is measured every 30 min for 30 hours at 30°C in a Tecan infinite M200 plate 
reader.  
 
 
 
